NLBNPIT23L79 20240920 320 (P23L79) News

Form 8-K - Current report

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Eton Pharmaceuticals Reports First Quarter 2024 Financial Results

•  Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of...

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative...

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi...

Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”...

Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic...

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive...

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024

DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”...

Form 8-K - Current report

Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation

DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or the “Company”) (Nasdaq:...

Form 4 - Statement of changes in beneficial ownership of securities